Fabry Disease Clinical Trial
Official title:
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy
FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and " renal variant " have been reported for FD patients with predominant or exclusive cardiac or renal involvement. " Neurologic variant " could exist. Nervous system can be affect by FD leading to cerebrovascular diseases (ischemic or haemorrhagic strokes, TIA (Transient Ischemic Attacks) or peripheral neuropathy (acroparesthesias and pain). Aims will be to determine the prevalence of Fabry disease in patients with stroke or small fiber neuropathy, and their characteristics
FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and " renal variant " have been reported for FD patients with predominant or exclusive cardiac or renal involvement. " Neurologic variant " could exist. Nervous system can be affect by FD leading to cerebrovascular diseases (ischemic or haemorrhagic strokes, TIA (Transient Ischemic Attacks) or peripheral neuropathy (acroparesthesias and pain). 1. Considering strokes, they are the third leading cause of death in France, with more than 140,000 people presenting a stroke per year. Stroke incidence is 1-2/1000 people per year. If the mean age of stroke patient is 72 yo, 25% of them are under 55 yo. The etiology of stroke in young patients remains undetermined in up to half of the cases. Data on prevalence of FD in people with cryptogenic ischaemic stroke are limited and controversial. In addition to cryptogenic strokes, FD can lead to stroke from arterial or heart diseases (secondary to high blood pressure, renal insufficiency, cardiomyopathy, rate variability, arrhythmias, valvular insufficiency). The investigators aimed to evaluate the frequency of FD in a cohort of stroke patients in tertiary stroke centers in consecutively recruited patients under 60 yo. The investigators will include patients with so-called cryptogenic stroke but also stroke patients due to large artery atherosclerosis, cardioembolism, and small-vessel occlusion. The investigators will also study the clinical and radiological characteristic of stroke patients due to FD, and will compare these data with those from patients without FD, supported by biochemical and genetic findings. 2. Considering peripheral nervous system, Small fiber neuropathy (SFN) is a subgroup of peripheral neuropathy which is characterized by an affection of the thin myelinated A-δ and unmyelinated C-fibers. SFN patients present with sensory symptoms and pain. SFN are not a rare condition; recent study showed a minimum prevalence of 50/100.000. The most commonly etiology reported for SFN is diabetes mellitus ; Other possible etiologies include connective tissue disease, celiac disease, thyroid dysfunction, vitamin B12 deficiency, monoclonal gammopathy, HIV and hepatitis C infections, amyloidosis, toxicity due to alcohol or drugs, and hereditary neuropathies including FD, suspected to be underdiagnosed. In SFN patients,the investigators aimed to screen for FD in our tertiary national center for peripheral neuropathies, in addition to others diseases or affections, to evaluate the frequency of FD in a large cohort of SFN patients, and describe the clinical phenotype of SFN in FD patients compared to other ones. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04893889 -
Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.
|
N/A | |
Completed |
NCT04455230 -
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
|
Phase 1/Phase 2 | |
Completed |
NCT01218659 -
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
|
Phase 3 | |
Completed |
NCT00304512 -
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
|
Phase 2 | |
Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
Completed |
NCT03500094 -
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
|
Phase 3 | |
Withdrawn |
NCT04143958 -
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
|
Phase 4 | |
Recruiting |
NCT02994303 -
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy
|
N/A | |
Completed |
NCT01947634 -
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
|
N/A | |
Recruiting |
NCT01695161 -
Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.
|
N/A | |
Completed |
NCT01853852 -
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
|
Phase 1 | |
Completed |
NCT00701415 -
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
|
Phase 3 | |
Completed |
NCT00068107 -
Dosing Study of Replagal in Patients With Fabry Disease
|
Phase 2 | |
Completed |
NCT01997489 -
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
|
Phase 4 | |
Recruiting |
NCT06007768 -
Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
|
||
Recruiting |
NCT05698901 -
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
|
||
Active, not recruiting |
NCT03305250 -
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease
|
N/A | |
Terminated |
NCT00526071 -
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
|
Phase 2 | |
Active, not recruiting |
NCT03566017 -
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
|
Phase 3 | |
Recruiting |
NCT06065605 -
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
|